BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol. 2008;103:2254-2262. [PMID: 18844615 DOI: 10.1111/j.1572-0241.2008.01974.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Siddiqui ZI, Farooqui SR, Azam SA, Afroz M, Wajid S, Parveen S, Kazim SN. A comparative study of hepatitis B virus X protein mutants K130M, V131I and KV130/131MI to investigate their roles in fibrosis, cirrhosis and hepatocellular carcinoma. J Viral Hepat 2017;24:1121-31. [PMID: 28654219 DOI: 10.1111/jvh.12747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Liu MH, Chen QY, Harrison TJ, Li GJ, Li H, Wang XY, Ju Y, Yang JY, Fang ZL. The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status. J Med Virol 2015;87:1351-60. [PMID: 25879734 DOI: 10.1002/jmv.24186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Qu L, Zhang H, Liu J, Liu T, Shen X, Chen T, Ni Z, Lu C. Potential Susceptibility Mutations in C Gene for Hepatitis B-Related Hepatocellular Carcinoma Identified by a Two-Stage Study in Qidong, China. Int J Mol Sci 2016;17:E1708. [PMID: 27727182 DOI: 10.3390/ijms17101708] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Lee JH, Han KH, Lee JM, Park JH, Kim HS. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Vaccine Immunol. 2011;18:914-921. [PMID: 21490166 DOI: 10.1128/cvi.00474-10] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
5 Jiang ZH, Chen QY, Harrison TJ, Li GJ, Wang XY, Li H, Hu LP, Li KW, Yang QL, Tan C, Fang ZL. Hepatitis B Virus Core Promoter Double Mutations (A1762T, G1764A) Are Associated with Lower Levels of Serum Dihydrolipoyl Dehydrogenase. Intervirology 2016;59:1-7. [PMID: 27303803 DOI: 10.1159/000445319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258-4270. [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Raihan R, Akbar SMF, Al Mahtab M, Takahashi K, Masumoto J, Tabassum S, Tee KK, Binti Mohamed R. Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh. PLoS One 2019;14:e0218744. [PMID: 31251754 DOI: 10.1371/journal.pone.0218744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24. [PMID: 20228847 DOI: 10.1038/onc.2010.36] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 16.7] [Reference Citation Analysis]
9 Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, Theamboonlers A, Poovorawan Y. A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int. 2010;4:577-584. [PMID: 21063480 DOI: 10.1007/s12072-010-9197-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
10 Li GJ, Chen QY, Harrison TJ, Wang XY, Hu LP, Yang QL, Li KW, Fang ZL. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study. Cancer Biomark 2017;18:241-8. [PMID: 28085009 DOI: 10.3233/CBM-160131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
12 Liu WB, Wu JF, Du Y, Cao GW. Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis. Curr Oncol 2016;23:e49-56. [PMID: 26966413 DOI: 10.3747/co.23.2836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Wang XY, Harrison TJ, Chen QY, Li H, Li GJ, Liu MH, Hu LP, Tan C, Yang QL, Fang ZL. The incidence rate over 10 years of naturally occurring, cancer related mutations in the basal core promoter of hepatitis B virus. Infect Genet Evol 2015;34:75-80. [PMID: 26192376 DOI: 10.1016/j.meegid.2015.07.020] [Reference Citation Analysis]
14 Zhang A, Wan Z, You S, Liu H, Zhu B, Chen J, Rong Y, Zang H, Li C, Wang H. Association of Hepatitis B Virus Mutations of A1846T and C1913A/G With Acute-on-Chronic Liver Failure Development From Different Underlying Chronic Liver Diseases. Hepat Mon. 2013;13:e12445. [PMID: 24282424 DOI: 10.5812/hepatmon.12445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
15 Chen QY, Wang XY, Harrison TJ, He X, Hu LP, Li KW, Jia HH, Yang QL, Wang C, Fang ZL. HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously. Epidemiol Infect 2017;145:728-38. [PMID: 27917751 DOI: 10.1017/S095026881600279X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101:1066-1082. [PMID: 19574418 DOI: 10.1093/jnci/djp180] [Cited by in Crossref: 255] [Cited by in F6Publishing: 262] [Article Influence: 21.3] [Reference Citation Analysis]
17 Malik A, Singhal DK, Albanyan A, Husain SA, Kar P. Hepatitis B virus gene mutations in liver diseases: a report from New Delhi. PLoS One. 2012;7:e39028. [PMID: 22720023 DOI: 10.1371/journal.pone.0039028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
18 An P, Xu J, Yu Y, Winkler CA. Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma. Front Genet 2018;9:261. [PMID: 30073017 DOI: 10.3389/fgene.2018.00261] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
19 Qu LS, Zhou GX. Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5999-6005 [PMID: 24876722 DOI: 10.3748/wjg.v20.i20.5999] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wu Y, Zhu Z, Wu J, Bi W, Xu W, Xia X, Han D. Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml. Front Public Health 2021;9:633792. [PMID: 33981663 DOI: 10.3389/fpubh.2021.633792] [Reference Citation Analysis]
21 Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, Lesi OA, Mendy M, Bah E, Friesen MD. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis. 2012;33:1219-1224. [PMID: 22759751 DOI: 10.1093/carcin/bgs135] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
22 Qu LS, Zhu J, Liu TT, Shen XZ, Chen TY, Ni ZP, Ni RZ, Lu CH. Effect of combined mutations in the enhancer II and basal core promoter of hepatitis B virus on development of hepatocellular carcinoma in Qidong, China. Hepatol Res. 2014;44:1186-1195. [PMID: 24341484 DOI: 10.1111/hepr.12291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
23 Wu Y, Gan Y, Gao F, Zhao Z, Jin Y, Zhu Y, Sun Z, Wu H, Chen T, Wang J. Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma. PLoS One. 2014;9:e94864. [PMID: 24788140 DOI: 10.1371/journal.pone.0094864] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
24 Li GJ, Harrison TJ, Yang JY, Chen QY, Wang XY, Fang ZL. Combined core promoter mutations and pre-S deletion of HBV may not increase the risk of HCC: a geographical epidemiological study in Guangxi, China. Liver Int 2013;33:936-43. [PMID: 23517325 DOI: 10.1111/liv.12142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
25 Tu WH, Lv Y, Zhang YM, Hou W, Wang JY, Zhang YJ, Liu HY, Zhu HX, Qin YL, Mao RC, Zhang JM. Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by Simpleprobe. World J Gastroenterol 2015; 21(21): 6639-6648 [PMID: 26074702 DOI: 10.3748/wjg.v21.i21.6639] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Caligiuri P, Cerruti R, Icardi G, Bruzzone B. Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol 2016; 22(1): 145-154 [PMID: 26755866 DOI: 10.3748/wjg.v22.i1.145] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 65] [Article Influence: 14.8] [Reference Citation Analysis]
27 Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma. Cancer Lett. 2014;343:161-171. [PMID: 24120759 DOI: 10.1016/j.canlet.2013.09.041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
28 Su YH, Lin SY, Song W, Jain S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn. 2014;14:803-817. [PMID: 25098554 DOI: 10.1586/14737159.2014.946908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
29 Wang XY, Huang JM, Lu XM, Harrison TJ, Liu HB, Jia HH, Fang ZL. Changing risk factors for hepatocellular carcinoma in hyperendemic regions in the era of universal hepatitis B vaccination. Cancer Epidemiol 2020;67:101775. [PMID: 32623359 DOI: 10.1016/j.canep.2020.101775] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dong H, Qian Z, Zhang L, Chen Y, Ren Z, Ji Q. Genomic and transcriptome profiling identified both human and HBV genetic variations and their interactions in Chinese hepatocellular carcinoma. Genom Data 2015;6:1-3. [PMID: 26697315 DOI: 10.1016/j.gdata.2015.07.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
31 Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ. The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J Hepatol. 2009;50:273-280. [PMID: 19070921 DOI: 10.1016/j.jhep.2008.09.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
32 Wang Y, Zhu Z, Zhang H, Zhu M, Xu X, Chen C, Liu L. Detection of hepatitis B virus A1762T/G1764A mutant by amplification refractory mutation system. The Brazilian Journal of Infectious Diseases 2014;18:261-5. [DOI: 10.1016/j.bjid.2013.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Kusakabe A, Tanaka Y, Inoue M, Kurbanov F, Tatematsu K, Nojiri S, Joh T, Tsugane S, Mizokami M. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol 2011;46:117-24. [PMID: 20820820 DOI: 10.1007/s00535-010-0307-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
34 Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 2011; 17(44): 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
35 Ji X, Zhang Q, Du Y, Liu W, Li Z, Hou X, Cao G. Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics. 2014;15:469-480. [PMID: 25646075 DOI: 10.2174/1389202915666141114213833] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
36 Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. J Med Virol 2010;82:1481-8. [PMID: 20648600 DOI: 10.1002/jmv.21845] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
37 Nie H, Evans AA, London WT, Block TM, Ren XD. Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach. J Clin Microbiol 2011;49:2440-8. [PMID: 21562108 DOI: 10.1128/JCM.02472-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Yan T, Li K, Li F, Su H, Mu J, Tong S, Patel M, Xia J, Wands JR, Wang H. T1846 and A/G1913 are associated with acute on chronic liver failure in patients infected with hepatitis B virus genotypes B and C. J Med Virol. 2011;83:996-1004. [PMID: 21503912 DOI: 10.1002/jmv.22067] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
39 Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101:1066-1082. [PMID: 19574418 DOI: 10.1093/jnci/djp180.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Ko HL, Zhuo Z, Ren EC. HNF4α Combinatorial Isoform Heterodimers Activate Distinct Gene Targets that Differ from Their Corresponding Homodimers. Cell Reports 2019;26:2549-2557.e3. [DOI: 10.1016/j.celrep.2019.02.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
41 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
42 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012;48:1977-87. [DOI: 10.1016/j.ejca.2012.01.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
43 Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol. 2011;106:81-92. [PMID: 20959817 DOI: 10.1038/ajg.2010.399] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 8.3] [Reference Citation Analysis]
44 Fang ZL, Hué S, Sabin CA, Li GJ, Yang JY, Chen QY, Fang KX, Huang J, Wang XY, Harrison TJ. A complex hepatitis B virus (X/C) recombinant is common in Long An county, Guangxi and may have originated in southern China. J Gen Virol. 2011;92:402-411. [PMID: 20965984 DOI: 10.1099/vir.0.026666-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
45 Zhang D, Ma S, Zhang X, Zhao H, Ding H, Zeng C. Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression. BMC Infect Dis. 2010;10:271. [PMID: 20846420 DOI: 10.1186/1471-2334-10-271] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
46 Fan W, Shi B, Wei H, Du G, Song S. Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. Virus Genes. 2011;42:162-170. [PMID: 21161360 DOI: 10.1007/s11262-010-0557-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
47 Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol. 2009;15:5761-5769. [PMID: 19998495 DOI: 10.3748/wjg.15.5761.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Yang Y, Sun JW, Zhao LG, Bray F, Xiang YB. Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies. Chin J Cancer Res 2015;27:497-508. [PMID: 26543337 DOI: 10.3978/j.issn.1000-9604.2015.10.05] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
49 Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, Lesi OA, Mendy M, Bah E, Friesen MD. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis. 2012;33:1219-1224. [PMID: 22759751 DOI: 10.1093/carcin/bgs068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
50 Iyer S, Groopman JD. Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival. Mol Carcinog. 2011;50:972-980. [PMID: 21438026 DOI: 10.1002/mc.20767] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
51 Mak D, Kramvis A. Molecular characterization of hepatitis B virus isolated from Black South African cancer patients, with and without hepatocellular carcinoma. Arch Virol 2020;165:1815-25. [PMID: 32504396 DOI: 10.1007/s00705-020-04686-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Huang J, Wang XY, Harrison TJ. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J Gen Virol. 2008;89:2882-2890. [PMID: 18931087 DOI: 10.1099/vir.0.2008/002824-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 5.8] [Reference Citation Analysis]
53 Nakabayashi J. The intracellular dynamics of hepatitis B virus (HBV) replication with reproduced virion "re-cycling". J Theor Biol 2016;396:154-62. [PMID: 26924390 DOI: 10.1016/j.jtbi.2016.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Wong VW, Chan SL, Mo F, Chan T, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. JCO 2010;28:1660-5. [DOI: 10.1200/jco.2009.26.2675] [Cited by in Crossref: 290] [Cited by in F6Publishing: 106] [Article Influence: 26.4] [Reference Citation Analysis]
55 Liu S, Xie J, Yin J, Zhang H, Zhang Q, Pu R, Li C, Ni W, Wang H, Cao G. A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J Med Virol. 2011;83:45-53. [PMID: 21108338 DOI: 10.1002/jmv.21829] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
56 Mendy M, Walton R. Molecular pathogenesis and early detection of hepatocellular carcinoma--perspectives from West Africa. Cancer Lett. 2009;286:44-51. [PMID: 19523756 DOI: 10.1016/j.canlet.2009.04.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
57 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 14.7] [Reference Citation Analysis]
58 Wang H, Cao G, Fu J, Lv G. Hepatitis Viruses and Hepatoma. In: Bast RC, Hait WN, Kufe DW, Weichselbaum RR, Holland JF, Croce CM, Piccart-gebart M, Wang H, Hong WK, Pollock RE, editors. Holland-Frei Cancer Medicine. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 1-6. [DOI: 10.1002/9781119000822.hfcm031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Liu H, Shen L, Zhang S, Wang F, Zhang G, Yin Z, Qiu F, Liang X, Wang F, Bi S. Complete genome analysis of hepatitis B virus in Qinghai-Tibet plateau: the geographical distribution, genetic diversity, and co-existence of HBsAg and anti-HBs antibodies. Virol J 2020;17:75. [PMID: 32532295 DOI: 10.1186/s12985-020-01350-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Qu LS, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One. 2014;9:e98257. [PMID: 24849936 DOI: 10.1371/journal.pone.0098257] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
61 Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15(46): 5761-5769 [PMID: 19998495 DOI: 10.3748/wjg.15.5761] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 100] [Article Influence: 7.8] [Reference Citation Analysis]
62 Du Y, Han X, Pu R, Xie J, Zhang Y, Cao G. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Front Med 2014;8:217-26. [PMID: 24748463 DOI: 10.1007/s11684-014-0326-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
63 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17(38): 4258-4270 [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
64 Chu CM, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer 2012;107:2010-5. [PMID: 23079574 DOI: 10.1038/bjc.2012.474] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
65 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36:1239-1251. [PMID: 27062182 DOI: 10.1111/liv.13142] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 13.0] [Reference Citation Analysis]
66 Xu L, Qian G, Tang L, Su J, Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol. 2010;53:671-676. [PMID: 20650537 DOI: 10.1016/j.jhep.2010.04.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
67 Chen QY, Harrison TJ, Sabin CA, Li GJ, Huang GM, Yang JY, Wang XY, Li H, Liu MH, Fang ZL. The Effect of HBV Genotype C on the Development of HCC Differs Between Wild-Type Viruses and Those With BCP Double Mutations (T(1762)A(1764)). Hepat Mon. 2014;14:e16214. [PMID: 24693312 DOI: 10.5812/hepatmon.16214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
68 Wang C, Teng Z, Zhu Y, Zhao AZ, Sun C. Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis. Med Sci Monit. 2015;21:1072-1077. [PMID: 25868851 DOI: 10.12659/msm.894058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
69 Liu WC, Wu IC, Lee YC, Lin CP, Cheng JH, Lin YJ, Yen CJ, Cheng PN, Li PF, Cheng YT, Cheng PW, Sun KT, Yan SL, Lin JJ, Yang JC, Chang KC, Ho CH, Tseng VS, Chang BC, Wu JC, Chang TT. Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus. J Pathol 2017;243:176-92. [PMID: 28696069 DOI: 10.1002/path.4938] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
70 Li KW, Kramvis A, Liang S, He X, Chen QY, Wang C, Yang QL, Hu LP, Jia HH, Fang ZL. Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults. Virus Res 2017;227:88-95. [PMID: 27720823 DOI: 10.1016/j.virusres.2016.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
71 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
73 Chen QY, Hu YL, Wang XY, Harrison TJ, Wang C, Hu LP, Yang QL, Ren CC, Jia HH, Fang AZ. Locus 5p13.1 may be associated with the selection of cancer-related HBV core promoter mutations. Int J Med Sci 2019;16:990-7. [PMID: 31341412 DOI: 10.7150/ijms.34297] [Reference Citation Analysis]
74 Qu L, Liu T, Jin F, Guo Y, Chen T, Ni Z, Shen X. Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: A nested case-control study in China: complex mutation patterns and HCC. Hepatology Research 2011;41:54-63. [DOI: 10.1111/j.1872-034x.2010.00732.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
75 Li W, Deng R, Liu S, Wang K, Sun J. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. Liver Int 2020;40:2316-25. [PMID: 32666675 DOI: 10.1111/liv.14607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
76 Liu Y, Zhao ZH, Lv XQ, Tang YW, Cao M, Xiang Q, Wu Y, Zhang HT, Lai GQ. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models. J Med Virol 2020. [PMID: 32427358 DOI: 10.1002/jmv.26025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Huang Y, Lok ASF. Viral Factors and Outcomes of Chronic HBV Infection. American Journal of Gastroenterology 2011;106:93-5. [DOI: 10.1038/ajg.2010.404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
78 Zhang Q, Yin J, Zhang Y, Deng Y, Ji X, Du Y, Pu R, Han Y, Zhao J, Han X. HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol. 2013;87:12176-12186. [PMID: 24006435 DOI: 10.1128/jvi.02073-13] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
79 Song XM, Li QL, Guo F, Peng H, Guo JJ. The Effect of ICOS Polymorphism Interactions with HBV Mutations on HBV Subtype Infection Outcomes. Ann Hepatol 2018;17:940-7. [PMID: 30600290 DOI: 10.5604/01.3001.0012.7194] [Reference Citation Analysis]
80 Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect 2015;21:969-74. [PMID: 26163104 DOI: 10.1016/j.cmi.2015.06.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]